Josi Holz

Josi joined Prokarium as part-time CMO in 2021. She received her training in medical oncology from the University of Marburg (Germany) and has over 25 years’ experience in pharmaceutical drug development in Europe and in North America. Josi held executive positions in international biotech companies (Ablynx NV, GPC-Biotech, U3 Pharma) and pharma organisations (Gilead Sciences, Bristol-Myers Squibb, OSI Pharmaceuticals, LEO Pharma). Josi’s portfolio experience covers more than 50 disease targets in oncology, immunology, inflammation, infectious diseases, haematology, bone disorders and dermatology in various stages of clinical validation. She also has in-depth experience in management of cross-company collaborative ventures, including partnerships with major pharma enterprises in Europe and North America and direct involvement in corporate financing initiative were part of her executive management functions.

Since 2015 Josi is an independent clinical advisor and frequently works in the function of a Part-time Chief Medical/Development Officer for biotechs. Her strategic focus is the clinically driven, stage-gate planning for biopharmaceutical companies, resulting in the successful transition of lead candidates into clinical development and product registration.

Additionally, Josi serves as medical advisor for the European Commission and is member of various medical associations such as ASCO, ESMO and SITC. She has published various articles, patents, gives invited talks and conference presentations on aspects of integrated drug development and translational research of biological medicinal products.